THE GLP-1 MICRODOSING PROGRAM
US$ 23.96
tirzepatide effect on liver Tirzepatide- A novel therapeutic against metabolic dysfunction-associated steatotic disease (MASLD) Tirzepatide vs Semaglutide Liver Damage
Description
Based on a meta-analysis of biopsy-based studies, optimal cut-offs of 248, 268 and 280 dB/m were reported for histological mild, moderate and severe steatosis respectively, achieving area under the curves of 0.820.89 [93]
Switching from semaglutide to tirzepatide requires a dose conversion to avoid either under-treatment or excessive initial dosing
No secondary conversion step
The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a Scandinavian cohort study